Claims
- 1. In the art of eliciting a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic neurotransmission male sexual activity response in penile erection, the improvement being a more rapid onset of action and improved effect than that of yohimbine, consisting essentially of the step of administering the compound atipamezole or a pharmaceutically acceptable acid addition salt thereof to a male in need thereof.
- 2. A method according to claim 1, wherein an effective amount of atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered to treat male sexual impotence.
- 3. A method according to claim 1, wherein said atipamezole or a pharmaceutically acceptable acid addition salt is administered perorally.
- 4. A method according to claim 3, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered in a dose range of 0.3 to 10 mg/kg.
- 5. A method according to claim 1, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered intravenously.
- 6. A method according to claim 5, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered in a dose range of 0.05 to 0.3 mg/kg.
- 7. A method according to claim 1, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered intramuscularly.
- 8. A method according to claim 7, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered in a dose range of 0.05 to 0.3 mg/kg.
- 9. A method according to claim 1, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered transmucosally.
- 10. A method according to claim 9, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered in a dose range of 0.05 of 0.3 mg/kg.
- 11. A method according to claim 1, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered transdermally.
- 12. A method according to claim 11, wherein said atipamezole or a pharmaceutically acceptable acid addition salt thereof is administered in a dose range of 0.05 to 0.3 mg/kg.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9113077 |
Jun 1991 |
GBX |
|
Parent Case Info
This application is a continuation of application Ser. No. 08/162,111, filed Dec. 10, 1993, now abandoned. This application was filed in the U.S. as an application under 35 U.S.C. .sctn.371 of PCT/FI92/00191, filed Jun. 18, 1992, published as WO92/22296, Dec. 23, 1992, which designated the United States.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4689339 |
Karjalainen et al. |
Aug 1987 |
|
Non-Patent Literature Citations (3)
Entry |
"Atipamezole", Drugs Future, vol. 15, No. 5, 1990, pp. 448-452. |
"Therapeutic Applications of Drugs Acting on Alpha-Adrenoceptors", E. MacDonald et al., Annals of Clinical Research, vol. 20, 1988, pp. 298-310. |
"Increased Sexual Behavior in Male Macaca arctoides Monkeys Produced by Atipamezole, a Selective .beta.-.sub.2 -Adrenoceptor Antagonist", Ilkka Linnakoski et al., Pharmacology Biochemistry and Behavior, vol. 42, 1992, Pergamon Press Ltd. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
162111 |
Dec 1993 |
|